Cargando…

Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism

Background: Amniotic fluid embolism (AFE) is a rare cause of severe maternal morbidity and mortality. No well-studied protocols are available for management of AFE. We present a case of cardiac arrest secondary to presumed AFE and the use of atropine-ondansetron-ketorolac (AOK). Case Report: A 34-ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Miranda, Martin, Jane, Biggio, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Division of Ochsner Clinic Foundation 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477128/
https://www.ncbi.nlm.nih.gov/pubmed/36189093
http://dx.doi.org/10.31486/toj.21.0107
_version_ 1784790289157718016
author Long, Miranda
Martin, Jane
Biggio, Joseph
author_facet Long, Miranda
Martin, Jane
Biggio, Joseph
author_sort Long, Miranda
collection PubMed
description Background: Amniotic fluid embolism (AFE) is a rare cause of severe maternal morbidity and mortality. No well-studied protocols are available for management of AFE. We present a case of cardiac arrest secondary to presumed AFE and the use of atropine-ondansetron-ketorolac (AOK). Case Report: A 34-year-old gravida 4, para 2012 underwent a repeat cesarean section at 39 weeks of gestation. After delivery of the placenta, hypoxia and hypotension developed, followed by cardiac arrest. Protocols for management of maternal cardiac arrest were followed. Echocardiogram demonstrated right ventricular dilation and hypokinesis. AOK was administrated during prolonged cardiac arrest, and spontaneous circulation returned. The patient was extubated on postoperative day 3 and discharged on postoperative day 10 without neurologic deficits. Conclusion: Management of AFE should include consideration of the addition of AOK to typical guidelines.
format Online
Article
Text
id pubmed-9477128
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Academic Division of Ochsner Clinic Foundation
record_format MEDLINE/PubMed
spelling pubmed-94771282022-09-29 Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism Long, Miranda Martin, Jane Biggio, Joseph Ochsner J Case Reports and Clinical Observations Background: Amniotic fluid embolism (AFE) is a rare cause of severe maternal morbidity and mortality. No well-studied protocols are available for management of AFE. We present a case of cardiac arrest secondary to presumed AFE and the use of atropine-ondansetron-ketorolac (AOK). Case Report: A 34-year-old gravida 4, para 2012 underwent a repeat cesarean section at 39 weeks of gestation. After delivery of the placenta, hypoxia and hypotension developed, followed by cardiac arrest. Protocols for management of maternal cardiac arrest were followed. Echocardiogram demonstrated right ventricular dilation and hypokinesis. AOK was administrated during prolonged cardiac arrest, and spontaneous circulation returned. The patient was extubated on postoperative day 3 and discharged on postoperative day 10 without neurologic deficits. Conclusion: Management of AFE should include consideration of the addition of AOK to typical guidelines. Academic Division of Ochsner Clinic Foundation 2022 2022 /pmc/articles/PMC9477128/ /pubmed/36189093 http://dx.doi.org/10.31486/toj.21.0107 Text en ©2022 by the author(s); Creative Commons Attribution License (CC BY) https://creativecommons.org/licenses/by/4.0/©2022 by the author(s); licensee Ochsner Journal, Ochsner Clinic Foundation, New Orleans, LA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (creativecommons.org/licenses/by/4.0/legalcode) that permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Case Reports and Clinical Observations
Long, Miranda
Martin, Jane
Biggio, Joseph
Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism
title Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism
title_full Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism
title_fullStr Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism
title_full_unstemmed Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism
title_short Atropine, Ondansetron, and Ketorolac: Supplemental Management of Amniotic Fluid Embolism
title_sort atropine, ondansetron, and ketorolac: supplemental management of amniotic fluid embolism
topic Case Reports and Clinical Observations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477128/
https://www.ncbi.nlm.nih.gov/pubmed/36189093
http://dx.doi.org/10.31486/toj.21.0107
work_keys_str_mv AT longmiranda atropineondansetronandketorolacsupplementalmanagementofamnioticfluidembolism
AT martinjane atropineondansetronandketorolacsupplementalmanagementofamnioticfluidembolism
AT biggiojoseph atropineondansetronandketorolacsupplementalmanagementofamnioticfluidembolism